EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis

Laura Schaupp iD, Annalisa Addante, Mirjam Völler, Kerstin Fentker iD, Aditi Kuppe, Markus Bardua, Julia Duerr iD, Linus Piehler, Jobst Röhmel iD, Stephanie Thee iD, Marieluise Kirchner, Matthias Ziehm iD und 8 weitere

European Respiratory Journal · 2023-08 · 62 (2) · 2202153

DOI: 10.1183/13993003.02153-2022 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Respiratory Journal, online erschienen am 06.07.2023. Verfasst von Laura Schaupp und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin,…. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 210-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent studies demonstrated that the triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves lung function and reduces pulmonary exacerbations in cystic fibrosis (CF) patients with at least one F508del allele. However, effects of ETI on downstream consequences of CFTR dysfunction, i.e. abnormal viscoelastic properties of airway mucus, chronic airway infection and inflammation have not been studied. The aim of this study was to determine the longitudinal effects of ETI on airway mucus rheology, microbiome and inflammation in CF patients with one or two F508del alleles aged ≥12 years throughout the first 12 months of therapy.

Methods

In this prospective observational study, we assessed sputum rheology, the microbiome, inflammation markers and proteome before and 1, 3 and 12 months after initiation of ETI.

Results

In total, 79 patients with CF and at least one F508del allele and 10 healthy controls were enrolled in this study. ETI improved the elastic modulus and viscous modulus of CF sputum at 3 and 12 months after initiation (all p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansSputumCystic Fibrosis Transmembrane Conductance RegulatorProteomeMutationPyrazolesPyridinesPyrrolidinesAminophenolsQuinolonesIndolesBenzodioxoles

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorProteomeelexacaftorPyrazolesPyridinesPyrrolidinesivacaftorAminophenolsQuinolonestezacaftor

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität…
  • German Center for Lung Research (DZL), associated partner site, Berlin, Germany.
  • L. Schaupp, A. Addante, M. Völler and K. Fentker contributed equally as first authors.
  • Proteomics Platform, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
  • Institute for Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Laura Schaupp, Kerstin Fentker, Julia Duerr, Jobst Röhmel, Stephanie Thee, Matthias Ziehm, Mirjam Stahl, Simon Y Graeber, Marcus A Mall

Förderung

  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Schaupp, L., Addante, A., Völler, M., Fentker, K., Kuppe, A., Bardua, M., Duerr, J., Piehler, L., Röhmel, J., Thee, S., Kirchner, M., Ziehm, M., Lauster, D., Haag, R., Gradzielski, M., Stahl, M., Mertins, P., Boutin, S., Graeber, S. Y., & Mall, M. A. (2023). Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. European Respiratory Journal, 62(2), 2202153. https://doi.org/10.1183/13993003.02153-2022

Vancouver

Schaupp L, Addante A, Völler M, Fentker K, Kuppe A, Bardua M, et al. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. European Respiratory Journal. 2023;62(2):2202153. doi:10.1183/13993003.02153-2022

BibTeX
@article{Schaupp2023,
  author = {Schaupp, Laura and Addante, Annalisa and Völler, Mirjam and Fentker, Kerstin and Kuppe, Aditi and Bardua, Markus and Duerr, Julia and Piehler, Linus and Röhmel, Jobst and Thee, Stephanie and Kirchner, Marieluise and Ziehm, Matthias and Lauster, Daniel and Haag, Rainer and Gradzielski, Michael and Stahl, Mirjam and Mertins, Philipp and Boutin, Sébastien and Graeber, Simon Y and Mall, Marcus A},
  title = {Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {62},
  number = {2},
  pages = {2202153},
  doi = {10.1183/13993003.02153-2022}
}
Kostenlos starten →